Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

2.50
Hdl Handle:
http://hdl.handle.net/10541/77735
Title:
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.
Authors:
Gridelli, Cesare; Ardizzoni, Andrea; Le Chevalier, Thierry; Manegold, Christian; Perrone, Francesco; Thatcher, Nick; Van Zandwijk, N; Di Maio, Massimo; Martelli, O; De Marinis, F
Abstract:
BACKGROUND: Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), but its benefit seems limited to fit patients with a performance status (PS) of 0 or 1. For PS2 patients, there is no consensus on standard treatment. With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced NSCLC in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April 2003. RESULTS: and conclusions On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients. Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.
Affiliation:
Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy. cgridelli@libero.it
Citation:
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. 2004, 15 (3):419-26 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
Mar-2004
URI:
http://hdl.handle.net/10541/77735
DOI:
10.1093/annonc/mdh087
PubMed ID:
14998843
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGridelli, Cesare-
dc.contributor.authorArdizzoni, Andrea-
dc.contributor.authorLe Chevalier, Thierry-
dc.contributor.authorManegold, Christian-
dc.contributor.authorPerrone, Francesco-
dc.contributor.authorThatcher, Nick-
dc.contributor.authorVan Zandwijk, N-
dc.contributor.authorDi Maio, Massimo-
dc.contributor.authorMartelli, O-
dc.contributor.authorDe Marinis, F-
dc.date.accessioned2009-08-18T14:55:52Z-
dc.date.available2009-08-18T14:55:52Z-
dc.date.issued2004-03-
dc.identifier.citationTreatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. 2004, 15 (3):419-26 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid14998843-
dc.identifier.doi10.1093/annonc/mdh087-
dc.identifier.urihttp://hdl.handle.net/10541/77735-
dc.description.abstractBACKGROUND: Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), but its benefit seems limited to fit patients with a performance status (PS) of 0 or 1. For PS2 patients, there is no consensus on standard treatment. With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced NSCLC in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April 2003. RESULTS: and conclusions On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients. Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshExpert Testimony-
dc.subject.meshHumans-
dc.subject.meshKarnofsky Performance Status-
dc.subject.meshLung Neoplasms-
dc.subject.meshNeoplasm Staging-
dc.titleTreatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, SG Moscati Hospital, Avellino, Italy. cgridelli@libero.iten
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.